Caplacizumab (His Tag)
Based on 2 publication(s) in Google Scholar
Caplacizumab (His Tag) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab (His Tag) inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab (His Tag) inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab (His Tag) can be used for the research of thrombotic thrombocytopenic purpura (TTP).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.83%
- CAS. Nr.: 915810-67-2
- Molecular Weight:29 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P9918
TremelimumabAnti-CTLA-4 mAb -
HY-P99796
OzoralizumabAnti-TNFα Antibody -
HY-P99397
SonelokimabAnti-IL-17A/F Antibody -
HY-P99115
EnvafolimabAnti PD-L1 Antibody -
HY-P990748
LunsekimigNanobody -
HY-P99638
GefurulimabAnti-C5/albumin Dual Antibody -
HY-P99003
Human IgG4 (S228P) kappa, Isotype ControlIgG4κ Isotype Control -
HY-P99947
RimteravimabBivalent VHH-Fc Antibody -
HY-P99385
VobarilizumabAnti-IL-6R/ALB mAB
Publications Citing Use of MedChemExpress (MCE) Caplacizumab (His Tag)
More
Customer Validation & Images
-
Histological Imaging/Staining
Biologische Aktivität
Beschreibung
Isotype
VH-VH
Species Reactivity
Human
IC50 & Target
VWF
In Vitro
Caplacizumab (His Tag) inhibits the binding of VWF with platelet glycoprotein (GP) Ibα in blood specimens[2].
Caplacizumab (His Tag) (0.8 μg/mL) can completely inhibit platelet adhesion to the collagen surface at high shear rates (>1500 s-1)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
Caplacizumab (His Tag) (at plasma levels between 0.3-0.5 μg/mL, i.v. bolus) shows a strong antithrombotic effect in a modified Folts model in baboons[4].
Caplacizumab (His Tag) (5 mg/kg total dose with intravenous and subcutaneous injection; intravenous injection first and subcutaneous injections follow) prevents middle cerebral artery thrombosis in a guinea pig model of middle cerebral artery thrombosis, and reduces brain damage without inducing hemorrhage[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Guinea pig (Dunkin-Hartley, male, 350-400 g) model of middle cerebral artery thrombosis[5]
-
Dosage:5 mg/kg total dose (0.4 mg/kg intravenously + 1.6 mg/kg subcutaneously at time 0 followed by 3 mg/kg subcutaneously 6 h later)
-
Administration:Intravenous injection first and subcutaneous injections follow
-
Result:Prevented thrombosis when administered immediately after and 15 min after complete occlusion of the middle cerebral artery.
Reduced brain damage area and did not increase intracerebral hemorrhage.
Reduced microvascular thrombosis in the ischemic brain tissue.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
VH-VH
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human VWF-A1 (1260–1554aa)-Fc can bind Caplacizumab. The EC50 for this effect is 7.442 ng/mL.
Chemical Information
-
CAS. Nr. 915810-67-2
-
Appearance Liquid
-
Molecular Weight 29 kDa
-
Color Colorless to light yellow
-
SMILES
[Caplacizumab (His Tag)]
-
Synonyms
ALX-0681; ALX-0081
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Caplacizumab (His Tag) purchased from MedChemExpress. Usage Cited in: Adv Ophthalmol Pract Res. 2025 Nov 21.
Representative images of the retinal flat-mounts stained with IB4 from OIR + Vehicle group, and OIR + ALX-0681 (Caplacizumab (His Tag), 1 μg/mL, diluted to a final volume of 1 μL before intravitreal injection into the right eye of P12 mice) group after OIR induction at P17. Neovascular and avascular areas are indicated by the white dots and white area, respectively.
-
Reinheit & Dokumentation
-
Data Sheet (264 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Maëlle le Besnerais, et al. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. [Content Brief]
[3]. Callewaert F, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012 Oct 25;120(17):3603-10. [Content Brief]
[4]. Ulrichts H, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011 Jul 21;118(3):757-65. [Content Brief]
[5]. Momi S, et al. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013 Jun 20;121(25):5088-97. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Caplacizumab (His Tag) Related Classifications
HY-P99227 Related Classifications
Powered by Bioz